Literature DB >> 15854805

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

Marina Vita1, Mohamed Abdel-Rehim, Susanne Olofsson, Zuzana Hassan, Lennart Meurling, Ake Sidén, Mabel Sidén, Tommy Pettersson, Moustapha Hassan.   

Abstract

The pharmacokinetics, biodistribution and the metabolic pathway of roscovitine were investigated in Sprague-Dawley rats after a single intravenous dose of 25 mg/kg. Blood, lungs, kidney, liver, testis, adipose tissue, spleen and brain were removed at different time-points. Plasma and tissue samples were analyzed using high performance liquid chromatography. The metabolites were identified using liquid chromatography/tandem mass spectrometry and nuclear magnetic resonance spectroscopy. Roscovitine (MW=354) was cleared rapidly from circulation and highly distributed to the tissues. The elimination half-life of roscovitine in plasma and tissues was short (<30 min). A major metabolite (M1) was observed mainly in plasma and in lower levels in all other tissues. M1 was identified as conversion of the hydroxyl-group at C2 to carboxylic acid (MW=368). A second metabolite (M2) was observed mainly in liver and kidney and identified as a hydroxylation product of the C8 of the purine-ring (MW=370). A third metabolite (M3) was found in several organs and corresponded to N-dealkylation of the N9-isopropyl side-chain (MW=312). Roscovitine concentrations in the brain were 30% of that observed in plasma, however no metabolites were detected in brain. In this investigation, three major metabolites of roscovitine were isolated and identified. Also, it was shown that roscovitine eliminates rapidly from both blood and tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854805     DOI: 10.1016/j.ejps.2005.02.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  21 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

3.  Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Authors:  Wolf Wrasidlo; Leslie A Crews; Igor F Tsigelny; Emily Stocking; Valentina L Kouznetsova; Diana Price; Amy Paulino; Tania Gonzales; Cassia R Overk; Christina Patrick; Edward Rockenstein; Eliezer Masliah
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

4.  The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.

Authors:  Moustapha Hassan; Hatem Sallam; Zuzana Hassan
Journal:  Sultan Qaboos Univ Med J       Date:  2011-05-15

5.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 6.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.

Authors:  Bénédicte Menn; Stéphane Bach; Teri L Blevins; Mark Campbell; Laurent Meijer; Serge Timsit
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 8.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine.

Authors:  Juan Sebastian Yakisich; Marina Fernanda Vita; Ake Siden; Deborah Ruth Tasat; Mabel Cruz
Journal:  Invest New Drugs       Date:  2009-04-24       Impact factor: 3.850

Review 10.  Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Fahad A Al-Abbasi; Mazin A Zamzami; Hasan A Al-Talhi; Mohammad A Kamal
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.